STOCKWATCH
·
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Corporate GovernanceApr 28, 2026, 06:07 AM

Corvex Amends 2025 10-K for Governance, Compensation, Officer Changes

AI Summary

Corvex, Inc. filed an Amendment No. 1 to its 2025 Annual Report (10-K/A) to amend Part III items related to Directors, Executive Officers, Corporate Governance, Executive Compensation, Security Ownership, Related Transactions, and Principal Accountant Fees. The amendment details changes in executive and director compensation for 2025, including the replacement of RSUs with discounted options due to liquidity challenges, and outlines a new 2026 director compensation policy. Additionally, the filing reports the termination of former CTO Michael Leabman and the appointments of Jay Crystal as CEO and Seth Demsey as a Director.

Key Highlights

  • Corvex (MOVE) filed 10-K/A amending Part III items (10-14) of its 2025 Annual Report.
  • Amendments cover Directors, Executive Officers, Corporate Governance, and Executive Compensation.
  • New certifications of principal executive and financial officers were filed as exhibits.
  • Due to 2025 liquidity challenges, executive and director RSUs were replaced with discounted options ($1.25 exercise price).
  • John Mastrototaro (COO) 2025 total compensation was $502,004; J. Cogan (CFO) was $528,032.
  • Michael Leabman (former CTO) employment terminated March 18, 2026, receiving $375,000 cash severance.
  • Jay Crystal appointed CEO on March 31, 2026; Seth Demsey appointed Director on March 19, 2026.
  • New 2026 Director Compensation Policy includes $65,000 annual retainer and $135,000 in annual equity awards.
MOVE
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Corvex, Inc.

Price Impact